ClinicalTrials.gg
CompletedNCT01212770PALACE 3Updated May 6, 2020Results posted

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

A Phase 3 interventional study of Apremilast 20mg and Apremilast 30mg in Psoriatic Arthritis, sponsored by Amgen. Completed at 91 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-06.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
2nd of 17
505 · median 219
Started
2010
with 3 others
Phase 3
8 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Read the detailed description

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Psoriatic Arthritis
  • Psoriasis
  • Arthritis
  • inflammation
  • skin condition
  • inflammatory cells
  • apremilast
  • CC-10004
  • phosphodiesterase type 4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged ≥ 18 years at time of consent.
  • Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.
  • Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.
  • Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)
  • May not have axial involvement alone
  • Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine
  • Have ≥ 3 swollen AND ≥ 3 tender joints.
  • Males \& Females must use
  • Stable dose of NSAIDs, narcotics and low dose oral allowed.
  • Have at least one ≥2 cm psoriasis lesion

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding.
  • History of allergy to any component of the product surface antigen and/or antibody positive at screening.
  • Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    Apremilast 20 mg

    20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase

    Drug: Apremilast 20mg

  • Experimental
    Apremilast 30 mg

    30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily

    Drug: Apremilast 30mg

  • Placebo comparator
    Placebo + 20 mg Apremilast

    Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16

    Drug: Placebo

  • Placebo comparator
    Placebo + 30 mg Apremilast

    Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

    Drug: Placebo

Interventions

  • Apremilast 20 mg twice daily, orally

    Also known as: CC-10004

  • Apremilast 30 mg twice daily, orally

    Also known as: CC-10004

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 16

  2. Percentage of Participants With an ACR 20 Response at Week 24

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 24

  4. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  5. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 16

  6. Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 16

    The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Week 16

  7. Change From Baseline in Patient's Assessment of Pain at Week 16

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 16

  8. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  9. Change From Baseline in Dactylitis Severity Score at Week 16

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  10. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 16

  11. Change From Baseline in the Disease Activity Score (DAS28) at Week 16

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 16

  12. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue.

    Time frame: Baseline and Week 16

  13. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  14. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 24

  15. Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 24

    The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 24 weeks of treatment. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Week 24

  16. Change From Baseline in Patient's Assessment of Pain at Week 24

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and week 24

  17. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and week 24

  18. Change From Baseline in Dactylitis Severity Score at Week 24

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  19. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

    Time frame: Baseline and Week 24

  20. Change From Baseline in the Disease Activity Score (DAS28) at Week 24

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 24

  21. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  22. Percentage of Participants With MASES Improvement ≥ 20% at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  23. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  24. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 16

  25. Percentage of Participants With MASES Improvement ≥ 20% at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  26. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  27. Percentage of Participants With Good or Moderate EULAR Response at Week 24

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 24

  28. Percentage of Participants With a ACR 50 Response at Week 16

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

  29. Percentage of Participants With an ACR 70 Response at Week 16

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

  30. Percentage of Participants With an ACR 50 Response at Week 24

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 24

  31. Percentage of Participants With a ACR 70 Response at Week 24

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 24

  32. Percentage of Participants Achieving a MASES Score of Zero at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 16

  33. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 16

  34. Percentage of Participants Achieving a MASES Score of Zero at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 24

  35. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 24

  36. Percentage of Participants With an ACR 20 Response at Week 52

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  37. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 52

  38. Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  39. Percentage of Participants With a Modified PsARC Response at Week 52

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  40. Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 52

    The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 52 weeks. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  41. Change From Baseline in the Patient Assessment of Pain at Week 52

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 52

  42. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 52

  43. Change From Baseline in the Dactylitis Severity Score at Week 52

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 52

  44. Change From Baseline in the CDAI Score at Week 52

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: •28 tender joint count (TJC), •28 swollen joint count (SJC), •Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; •Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 52

  45. Change From Baseline in the DAS28 at Week 52

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: •28 tender joint count •28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; •C-reactive protein (CRP) •Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 52

  46. Change From Baseline in the FACIT-Fatigue Scale Score at Week 52

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  47. Percentage of Participants With MASES Improvement ≥ 20% at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  48. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  49. Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  50. Percentage of Participants With an ACR 50 Response at Week 52

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  51. Percentage of Participants With an ACR 70 Response at Week 52

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  52. Percentage of Participants Achieving a MASES Score of Zero at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  53. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  54. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase

    A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

    Time frame: Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)

  55. Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

    A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

    Time frame: Week 0 to Week 260; median duration of exposure to apremilast 20 mg BID was 121.71 weeks and 232.50 weeks for apremilast 30 mg BID

07

Results

Posted May 20, 2014

Participant flow

The study was conducted at 78 study centers in 16 countries.

Placebo-controlled Phase (Week 0 - 24)
Participant flow — Placebo-controlled Phase (Week 0 - 24)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started169169167000000
Received treatment169169167000000
Completed week 16156157156000000
Early escape at week 16977653000000
Completed146147145000000
Not completed232222000000
Withdrew: Adverse event10128000000
Withdrew: Lack of efficacy657000000
Withdrew: Withdrawal by subject341000000
Withdrew: Lost to follow-up103000000
Withdrew: Protocol violation001000000
Withdrew: Miscellaneous312000000
Active Treatment Phase (Weeks 25 - 52)
Participant flow — Active Treatment Phase (Weeks 25 - 52)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started01391384325472500
Completed01201263223442300
Not completed019121123200
Withdrew: Adverse event062200100
Withdrew: Lack of efficacy075412000
Withdrew: Withdrawal by subject063311100
Withdrew: Lost to follow-up001000000
Withdrew: Protocol violation000100000
Withdrew: Miscellaneous001100000
Long-term Safety Phase (Year 2)
Participant flow — Long-term Safety Phase (Year 2)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started011112100005164
Completed08810600004250
Not completed023150000914
Withdrew: Adverse event033000002
Withdrew: Lack of efficacy067000046
Withdrew: Non-compliance to study drug010000000
Withdrew: Withdrawal by subject093000044
Withdrew: Lost to follow-up021000011
Withdrew: Miscellaneous021000001
Long-term Safety Phase (Year 3)
Participant flow — Long-term Safety Phase (Year 3)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started08710500004249
Completed0769400003544
Not completed01111000075
Withdrew: Adverse event022000021
Withdrew: Lack of efficacy034000022
Withdrew: Withdrawal by subject034000011
Withdrew: Lost to follow-up010000000
Withdrew: Protocol violation000000010
Withdrew: Miscellaneous021000011
Long-term Safety Phase (Year 4)
Participant flow — Long-term Safety Phase (Year 4)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0779400003544
Completed0718300003242
Not completed0611000032
Withdrew: Adverse event011000001
Withdrew: Lack of efficacy015000020
Withdrew: Non-compliance with study drug011000010
Withdrew: Withdrawal by subject023000000
Withdrew: Lost to follow-up001000000
Withdrew: Miscellaneous010000001
Long-term Safety Phase (Year 5)
Participant flow — Long-term Safety Phase (Year 5)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0708300003242
Completed0687200003041
Not completed0211000021
Withdrew: Missing001000000
Withdrew: Miscellaneous003000000
Withdrew: Adverse event002000001
Withdrew: Lack of efficacy004000000
Withdrew: Withdrawal by subject021000010
Withdrew: Death000000010

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1618.328.440.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 22.3 · 95% CI 13.0 to 31.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0295 · Adjusted difference: 9.8 · 95% CI 1.1 to 18.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16-0.065 ± 0.0335-0.131 ± 0.0337-0.192 ± 0.0339
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0073 · Ls mean difference: -0.127 · 95% CI -0.220 to -0.034Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1619 · Ls mean difference: -0.066 · 95% CI -0.158 to 0.027Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryPercentage of Participants With an ACR 20 Response at Week 24

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 20 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 20 Response at Week 2415.426.631.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0007 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 15.5 · 95% CI 6.7 to 24.3Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0110 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 11.1 · 95% CI 2.7 to 19.5Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24-0.053 ± 0.0350-0.137 ± 0.0351-0.192 ± 0.0353
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0050 · Ls mean difference: -0.139 · 95% CI -0.236 to -0.042Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0860 · Ls mean difference: -0.084 · 95% CI -0.181 to 0.012Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 161.14 ± 0.5892.29 ± 0.5923.47 ± 0.594
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0053 · Ls mean difference: 2.32 · 95% CI 0.69 to 3.95Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1658 · Ls mean difference: 1.15 · 95% CI -0.48 to 2.77Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 1627.237.952.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 25.4 · 95% CI 15.5 to 35.3Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0372 · Adjusted difference: 10.4 · 95% CI 0.8 to 20.0Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 16

The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 167.920.922.2
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0062 · Adjusted difference: 14.6 · 95% CI 4.5 to 24.8Adjusted difference is the weighted average of the treatment differences across 2 strata of baseline DMARD use with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0134 · Adjusted difference: 13.0 · 95% CI 3.0 to 23.1Adjusted difference is the weighted average of the treatment differences across 2 strata of baseline DMARD use with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 16

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 16
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 16-4.9 ± 1.79-8.6 ± 1.80-12.7 ± 1.81
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0021 · Ls mean difference: -7.8 · 95% CI -12.8 to -2.9Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1482 · Ls mean difference: -3.6 · 95% CI -8.6 to 1.3Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16-0.7 ± 0.27-0.7 ± 0.29-1.0 ± 0.27
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.5349 · Ls mean difference: -0.2 · 95% CI -1.0 to 0.5Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.8231 · Ls mean difference: 0.1 · 95% CI -0.7 to 0.9Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 16

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 16-1.3 ± 0.34-1.7 ± 0.33-2.1 ± 0.32
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0720 · Ls mean difference: -0.8 · 95% CI -1.7 to 0.1Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.3641 · Ls mean difference: -0.4 · 95% CI -1.3 to 0.5Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16-2.76 ± 0.869-4.61 ± 0.886-7.70 ± 0.881
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0001 · Ls mean difference: -4.94 · 95% CI -7.34 to -2.53Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1325 · Ls mean difference: -1.85 · 95% CI -4.27 to 0.56Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 16

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 16-0.28 ± 0.084-0.54 ± 0.085-0.74 ± 0.085
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0001 · Ls mean difference: -0.47 · 95% CI -0.70 to -0.24Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0237 · Ls mean difference: -0.27 · 95% CI -0.50 to -0.04Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 161.18 ± 0.6401.86 ± 0.6433.72 ± 0.641
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0049 · Ls mean difference: 2.54 · 95% CI 0.77 to 4.30Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.4505 · Ls mean difference: 0.68 · 95% CI -1.09 to 2.44Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 241.03 ± 0.5812.71 ± 0.5823.37 ± 0.585
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0043 · Ls mean difference: 2.34 · 95% CI 0.74 to 3.94Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0404 · Ls mean difference: 1.67 · 95% CI 0.07 to 3.27Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 2423.132.044.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = < 0.0001 · Adjusted difference: 21.2 · 95% CI 11.5 to 30.9Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0661 · Adjusted difference: 8.7 · 95% CI -0.5 to 18.0Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 24

The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 24 weeks of treatment. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 2411.222.225.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0099 · Adjusted difference: 14.8 · 95% CI 3.8 to 25.7Adjusted difference is the weighted average of the treatment differences across 2 strata of baseline DMARD use with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0515 · Adjusted difference: 10.8 · 95% CI 0.1 to 21.4Adjusted difference is the weighted average of the treatment differences across 2 strata of baseline DMARD use with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 24

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 24
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 24-4.4 ± 1.75-8.2 ± 1.76-10.9 ± 1.77
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0080 · Ls mean difference: -6.6 · 95% CI -11.4 to -1.7Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1218 · Ls mean difference: -3.8 · 95% CI -8.6 to 1.0Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24-0.7 ± 0.29-1.0 ± 0.31-1.1 ± 0.29
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.2761 · Ls mean difference: -0.4 · 95% CI -1.3 to 0.4Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.5012 · Ls mean difference: -0.3 · 95% CI -1.1 to 0.6Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 24

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 24-1.3 ± 0.35-1.7 ± 0.34-2.3 ± 0.32
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0399 · Ls mean difference: -1.0 · 95% CI -1.9 to -0.0Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.4413 · Ls mean difference: -0.4 · 95% CI -1.3 to 0.6Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-2.53 ± 0.889-5.18 ± 0.900-7.81 ± 0.895
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = < 0.0001 · Ls mean difference: -5.27 · 95% CI -7.73 to -2.82Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0349 · Ls mean difference: -2.65 · 95% CI -5.11 to -0.19Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 24

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 24-0.27 ± 0.087-0.57 ± 0.088-0.75 ± 0.087
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0001 · Ls mean difference: -0.48 · 95% CI -0.72 to -0.24Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0147 · Ls mean difference: -0.30 · 95% CI -0.54 to -0.06Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 240.83 ± 0.6522.01 ± 0.6513.27 ± 0.654
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0078 · Ls mean difference: 2.44 · 95% CI 0.64 to 4.24Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1936 · Ls mean difference: 1.19 · 95% CI -0.61 to 2.98Based on an ANCOVA model with treatment group, baseline DMARD use and ≥ 3% BSA psoriasis involvement as factors and the baseline value as a covariate.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 1653.248.554.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.7585 · Adjusted difference: 2.1 · 95% CI -10.9 to 15.0Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.5808 · Adjusted difference: -3.9 · 95% CI -17.4 to 9.7Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 1659.266.271.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1303 · Adjusted difference: 12.0 · 95% CI -3.1 to 27.0Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3610 · Adjusted difference: 7.5 · 95% CI -8.3 to 23.2Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 1629.040.251.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = < 0.0001 · Adjusted difference: 22.5 · 95% CI 12.4 to 32.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0309 · Adjusted difference: 11.0 · 95% CI 1.2 to 20.9Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 2451.451.554.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.5731 · Adjusted difference: 3.8 · 95% CI -9.1 to 16.7Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.8876 · Adjusted difference: 1.0 · 95% CI -12.6 to 14.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 2460.667.673.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1172 · Adjusted difference: 12.2 · 95% CI -2.5 to 26.9Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3695 · Adjusted difference: 7.2 · 95% CI -8.2 to 22.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate EULAR Response at Week 24

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate EULAR Response at Week 2420.132.042.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = < 0.0001 · Adjusted difference: 22.5 · 95% CI 13.0 to 32.1Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0123 · Adjusted difference: 11.7 · 95% CI 2.7 to 20.7Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 50 Response at Week 16

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 50 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 50 Response at Week 168.312.415.0
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0520 · Adjusted difference: 6.8 · 95% CI 0.0 to 13.5Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.2052 · Adjusted difference: 4.2 · 95% CI -2.2 to 10.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 70 Response at Week 16

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 162.44.73.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.5154 · Adjusted difference: 1.2 · 95% CI -2.4 to 4.8Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.2527 · Adjusted difference: 2.3 · 95% CI -1.5 to 6.2Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 50 Response at Week 24

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 247.713.616.2
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0180 · Adjusted difference: 8.3 · 95% CI 1.6 to 15.1Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0807 · Adjusted difference: 5.8 · 95% CI -0.6 to 12.3Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 70 Response at Week 24

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 70 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 70 Response at Week 243.64.15.4
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.4230 · Adjusted difference: 1.8 · 95% CI -2.6 to 6.2Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.7870 · Adjusted difference: 0.6 · 95% CI -3.5 to 4.6Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 1624.819.620.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.4707 · Adjusted difference: -4.1 · 95% CI -14.8 to 6.5Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3547 · Adjusted difference: -5.4 · 95% CI -16.6 to 5.7Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 1635.240.841.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.4175 · Adjusted difference: 6.6 · 95% CI -8.6 to 21.8Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.4370 · Adjusted difference: 6.4 · 95% CI -9.1 to 21.8Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 2428.420.627.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.9463 · Adjusted difference: -0.4 · 195% CI -12.1 to 11.3Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.2032 · Adjusted difference: -7.7 · 95% CI -19.3 to 3.8Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 2436.645.146.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.2321 · Adjusted difference: 9.8 · 95% CI -5.8 to 25.4Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.2520 · Adjusted difference: 9.6 · 95% CI -6.2 to 25.3Adjusted difference is the weighted average of the treatment differences across 4 strata of baseline DMARD use by ≥ 3% BSA psoriasis involvement at baseline with the CMH weights. The 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 20 Response at Week 52

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 20 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 20 Response at Week 5259.3 (45.0 to 72.4)58.2 (45.5 to 70.2)56.0 (46.5 to 65.2)63.0 (54.0 to 71.4)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52-0.34 ± 0.407-0.34 ± 0.491-0.33 ± 0.505-0.35 ± 0.505
SecondaryChange From Baseline in the SF-36 Physical Functioning Scale Score at Week 52

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 527.76 ± 8.2366.87 ± 7.2415.68 ± 8.4675.87 ± 8.008
SecondaryPercentage of Participants With a Modified PsARC Response at Week 52

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified PsARC Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified PsARC Response at Week 5281.1 (68.0 to 90.6)75.8 (63.6 to 85.5)71.6 (62.4 to 79.5)79.0 (70.8 to 85.8)
SecondaryPercentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 52

The percentage of participants with Baseline psoriasis body surface area (BSA) involvement ≥ 3% who achieved 75% or greater improvement from Baseline in Psoriasis Area and Severity Index (PASI) score after 52 weeks. The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 5233.3 (15.6 to 55.3)28.6 (14.6 to 46.3)28.6 (17.9 to 41.3)39.1 (27.1 to 52.1)
SecondaryChange From Baseline in the Patient Assessment of Pain at Week 52

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 52
Reported as:
Mean · mm
Change From Baseline in the Patient Assessment of Pain at Week 52
mmPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Patient Assessment of Pain at Week 52-19.9 ± 24.54-19.1 ± 26.95-14.9 ± 24.86-18.7 ± 27.01
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52-2.5 ± 3.10-2.2 ± 3.01-2.2 ± 2.98-1.9 ± 2.99
SecondaryChange From Baseline in the Dactylitis Severity Score at Week 52

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Dactylitis Severity Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Dactylitis Severity Score at Week 52-3.1 ± 4.26-3.8 ± 4.52-2.9 ± 3.67-3.6 ± 4.30
SecondaryChange From Baseline in the CDAI Score at Week 52

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: •28 tender joint count (TJC), •28 swollen joint count (SJC), •Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; •Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the CDAI Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the CDAI Score at Week 52-13.54 ± 10.689-12.38 ± 10.308-12.86 ± 12.654-14.14 ± 11.354
SecondaryChange From Baseline in the DAS28 at Week 52

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: •28 tender joint count •28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; •C-reactive protein (CRP) •Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the DAS28 at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the DAS28 at Week 52-1.28 ± 1.102-1.29 ± 1.156-1.21 ± 1.063-1.41 ± 1.204
SecondaryChange From Baseline in the FACIT-Fatigue Scale Score at Week 52

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the FACIT-Fatigue Scale Score at Week 526.72 ± 8.9965.66 ± 8.7384.78 ± 8.5266.20 ± 8.679
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 5273.5 (55.6 to 87.1)75.0 (60.4 to 86.4)77.3 (65.3 to 86.7)71.3 (60.6 to 80.5)
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 5295.5 (77.2 to 99.9)92.3 (74.9 to 99.1)88.5 (76.6 to 95.6)91.8 (81.9 to 97.3)
SecondaryPercentage of Participants Achieving Good or Moderate EULAR Response at Week 52

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 5264.873.169.474.8
SecondaryPercentage of Participants With an ACR 50 Response at Week 52

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 5228.3 (16.8 to 42.3)31.8 (20.9 to 44.4)25.2 (17.7 to 34.0)30.2 (22.3 to 39.0)
SecondaryPercentage of Participants With an ACR 70 Response at Week 52

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 5220.8 (10.8 to 34.1)14.9 (7.4 to 25.7)9.2 (4.7 to 15.8)10.4 (5.7 to 17.1)
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 5244.1 (27.2 to 62.1)43.8 (29.5 to 58.8)33.3 (22.2 to 46.0)36.8 (26.7 to 47.8)
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 5268.2 (45.1 to 86.1)80.8 (60.6 to 93.4)75.0 (61.1 to 86.0)68.9 (55.7 to 80.1)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase

A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

Time frame:
Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
participantsPlaceboApremilast 20 mgApremilast 30 mg
Any TEAE83100104
Any Drug-Related TEAE335062
Any Severe TEAE8510
Any Serious TEAE (SAE)936
Any Serious Drug-Related TEAE200
Any TEAE Leading to Drug Interruption42016
Any TEAE Leading to Drug Withdrawal101312
Any TEAE Leading to Death000
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

Time frame:
Week 0 to Week 260; median duration of exposure to apremilast 20 mg BID was 121.71 weeks and 232.50 weeks for apremilast 30 mg BID
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
participantsApremilast 20 mg (Pre-switch)Apremilast 20/30 mg (Post-switch)Apremilast 30 mg
Any TEAE19464209
Any Drug-Related TEAE9811111
Any Severe TEAE21030
Any Serious TEAE (SAE)38454
Any Serious Drug-Related TEAE503
Any TEAE Leading to Drug Interruption48453
Any TEAE Leading to Drug Withdrawal30030
Any TEAE Leading to death010

Adverse events

Collected over AEs are reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants and reported for the Apremilast Exposure Period from Week 0 to Week 260; median duration of apremilast 20 mg BID was 121.71 weeks and 232.50 weeks for apremilast 30 mg twice daily. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Weeks 0-24: Placebo (Placebo-Controlled Phase)—9/168 (5.4%)35/168 (20.8%)
Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)—4/170 (2.4%)66/170 (38.8%)
Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)—6/167 (3.6%)71/167 (42.5%)
APR Exposure Period Up to 5 Years: Apremilast 20 mg—38/241 (15.8%)142/241 (58.9%)
APR Exposure Period Up to 5 Years: Apremilast 20mg/30 mg—4/97 (4.1%)36/97 (37.1%)
APR Exposure Period Up to 5 Years: Apremilast 30 mg—54/242 (22.3%)164/242 (67.8%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)APR Exposure Period Up to 5 Years: Apremilast 20 mgAPR Exposure Period Up to 5 Years: Apremilast 20mg/30 mgAPR Exposure Period Up to 5 Years: Apremilast 30 mg
Psoriatic arthropathyMusculoskeletal and connective tissue disorders2/1681/1701/1672/2410/977/242
OsteoarthritisMusculoskeletal and connective tissue disorders0/1680/1700/1673/2410/972/242
Pancreatitis acuteGastrointestinal disorders2/1680/1700/1670/2410/970/242
Cardiac failureCardiac disorders0/1680/1700/1671/2411/970/242
Sick sinus syndromeCardiac disorders0/1680/1700/1670/2411/970/242
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1680/1700/1670/2411/971/242
AnxietyPsychiatric disorders0/1680/1700/1670/2411/970/242
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1680/1700/1670/2411/970/242
Angina unstableCardiac disorders0/1680/1700/1672/2410/972/242
PneumoniaInfections and infestations0/1680/1700/1672/2410/971/242
Most frequent other events
Showing 10 of 16
Most frequent other events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)APR Exposure Period Up to 5 Years: Apremilast 20 mgAPR Exposure Period Up to 5 Years: Apremilast 20mg/30 mgAPR Exposure Period Up to 5 Years: Apremilast 30 mg
NauseaGastrointestinal disorders9/16819/17023/16728/2413/9747/242
DiarrhoeaGastrointestinal disorders3/16826/17026/16740/2411/9744/242
HeadacheNervous system disorders8/16816/17020/16730/2414/9739/242
NasopharyngitisInfections and infestations2/1687/1704/16734/24112/9736/242
Upper respiratory tract infectionInfections and infestations3/16811/17012/16734/2416/9736/242
Urinary tract infectionInfections and infestations1/1682/1705/16719/2413/9722/242
HypertensionVascular disorders5/1683/1704/16717/2413/9722/242
BronchitisInfections and infestations2/1683/1701/16717/2413/9720/242
ArthralgiaMusculoskeletal and connective tissue disorders3/1682/1704/1679/2410/9719/242
SinusitisInfections and infestations3/1684/1704/16712/2411/9718/242

Baseline characteristics

The full analysis dataset (FAS) consisted of all participants who were randomized as specified in the protocol.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean49.5 ± 11.6449.6 ± 12.1049.9 ± 11.3849.7 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Female919088269
Male787979236
Duration of psoriatic arthritis
Duration of psoriatic arthritis(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean6.78 ± 6.4637.74 ± 7.6907.48 ± 7.6467.33 ± 7.284
08

Study locations

91 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Catalina Pointe Clinical Research Incorporated
    Tucson, Arizona 85704, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Joao Nascimento, MD
    Bridgeport, Connecticut 6606, United States
  • In Vivo Clinical Research
    Doral, Florida 33166, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Rheumatology Associates of Long Island
    Orlando, Florida 32806, United States
  • Advent Clinical Research
    Pinellas Park, Florida 33781, United States
  • Rockford Orthopedic Associates, LLC
    Rockford, Illinois 61107, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • DermResearch, PLLC
    Louisville, Kentucky 40217, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • STAT Research, Inc.
    Dayton, Ohio 45417, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Austin Regional Clinic
    Austin, Texas 78731, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Houston Medical Research
    Houston, Texas 77090, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Skin Cancer Foundation
    Carlton, 3053, Australia
  • Coff's Clinical Trials
    Coffs Harbour, 2450, Australia
  • Heidelberg Repatriation Hospital
    Heidelberg, 3081, Australia
  • Menzies Centre for Population Health Research
    Hobart, 7000, Australia
  • Optimus Clinical Research Pty. Ltd
    Kogarah, 2217, Australia
  • Coastal Joint Care
    Maroochydore, 4558, Australia
  • The Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • Arthritis Research Centre of Canada
    Vancouver, British Columbia V5Z1L7, Canada
  • PerCuro Clinical Research
    Victoria, British Columbia V8P5P6, Canada
  • Manitoba Clinic
    Winnipeg, Manitoba R3A1M3, Canada
  • Arthritis Centre
    Winnipeg, Manitoba R3A1M4, Canada
  • Alpha Clinical Research, LLC
    St John's, Newfoundland and Labrador A1B 4S8, Canada
  • Niagara Peninsula Arthritis Centre Inc.
    St Catharines, Ontario L2N 7E4, Canada
  • Manna Research
    Toronto, Ontario M9W4L6, Canada
  • Helsingin Reumakeskus Oy
    Helsinki, FI-00120, Finland
  • Helsingin yliopistollinen keskussairaala
    Helsinki, FI-00290, Finland
  • Finnish Medical Research Co
    Pori, FI-28100, Finland
  • Centre Hospitalier Sud Francilien - Site Gilles de Corbeil
    Corbeil Essonnes, 91106, France
  • Hôtel-Dieu
    Nantes, 44093, France
  • Groupe Hospitalier Archet I et II
    Nice, 6002, France
  • Hopital Larrey Universite Paul Sabatier
    Toulouse, 31000, France
  • Charite - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Klinische Forschung Berlin - Buch GmbH
    Berlin, 13125, Germany
  • Klinikum der Friedrich-Schiller-Universität Jena
    Jena, 7740, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Roma, 133, Italy
  • Hallym University Sacred Heart Hospital
    Anyang, Kyunggi, 431070, Korea, Republic of
  • Chungnam National University Hospital
    DaeJeon, 301-721, Korea, Republic of
  • Inha University Hosiptal
    Incheon, 400-711, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 405760, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Ajou University Hospital
    Suwon, 443-721, Korea, Republic of
  • Hospital of Lithuanian University Health and Sciences
    Kaunas, LT-50009, Lithuania
  • Klaipeda University Hospital
    Klaipeda, LT-5808, Lithuania
  • Panevezys Hospital
    Panevezys, LT-35144, Lithuania
  • Siauliai Hospital
    Siauliai, LT-76231, Lithuania
  • Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
    Bialystok, 15-099, Poland
  • Centrum Medyczne Silesiana Sp. z o.o.
    Bytom, 41-902, Poland
  • Malopolskie Centrum Medyczne S.C.
    Kraków, 30-510, Poland
  • Prywatna Praktyka Lekarska Pawel Hrycaj
    Poznan, 61-397, Poland
  • REUMATIKA-Centrum Reumatologii Niepubliczny Zaklad Opieki Zdrowotnej
    Warszawa, 02-653, Poland
  • Baia Mare, Emergency County Hospital "Dr. Constantin Opris"
    Baia Mare, 430031, Romania
  • SC Duo Medical SRL
    Bucharest, 10584, Romania
  • Sf. Maria Clinical Hospital
    Bucharest, 11172, Romania
  • Emergency County Clinical Hospital
    Cluj-Napoca, 400006, Romania
  • Sf Apostol Andrei Emergency Clinical County Hospital
    Galati, 800578, Romania
  • C.M.I. Dr. Ciornohuz Adriana
    Iasi, 700127, Romania
  • Sverdlovsk Regional Clinical Hospital 1
    Ekaterinburg, 620102, Russian Federation
  • Research Medical Complex Vashe Zdorovie
    Kezch, 214025, Russian Federation
  • Research Institute of Clinical and Experimental Lymphology
    Novosibirsk, 630117, Russian Federation
  • Penza Regional Clinical Hospital n.a. N.N. Burdenko
    Penza, 440026, Russian Federation
  • City Hospital 26
    St. Petersburg, 196247, Russian Federation
  • Narodny ustav reumatickych chorob
    Piestany, 921 12, Slovakia
  • MUDr. Zuzana Cizmarikova, s.r.o.
    Poprad,Spisska Sobota, 058 01, Slovakia
  • REUMEX s.r.o.
    Rimavska Sobota, 979 01, Slovakia
  • Hospital Universitario a Coruna
    A Coruña, 15006, Spain
  • Hospital de Basurto-Osakidetza
    Bilbao, 48013, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, 33006, Spain
  • Hospital Infanta Sofia
    San Sebastian de los Reyes, 28702, Spain
  • HFR Fribourg - Hôpital Cantonal
    Fribourg, 1708, Switzerland
  • Chuv Bh-04
    Lausanne, 1011, Switzerland
  • Kantonsspital St. Gallen
    St. Gallen, 9007, Switzerland
  • Haywood Hospital
    Burslem, ST6 7AG, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20. PubMed 26792812 ↗
  • Mease PJ, Gladman DD, Kavanaugh A, McGonagle D, Nash P, Guerette B, Nakasato P, Brunori M, Teng L, McInnes IB. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatol Ther. 2021 Dec;8(4):1677-1691. doi: 10.1007/s40744-021-00369-x. Epub 2021 Sep 18. PubMed 34536218 ↗
  • Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, McInnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res (Hoboken). 2020 Jun;72(6):814-821. doi: 10.1002/acr.24134. Epub 2020 May 8. PubMed 31909868 ↗
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3. PubMed 31077258 ↗
  • Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. PubMed 30018799 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Aug 2012, 22 months.

Results were first posted in May 2014, 1 year 8 months after primary completion. A results delay was requested in Jul 2013.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 22 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Oct 1, 2010
StartActual
Sep 30, 2010
Primary completionActual
Aug 21, 2012
CompletionActual
Feb 9, 2017
Results delay requested
Jul 23, 2013
Results first posted
May 20, 2014
Last update
May 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01212770
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 1, 2010
Start date
Sep 30, 2010
Primary completion
Aug 21, 2012
Completion
Feb 9, 2017
Results posted
May 20, 2014
Last update
May 6, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion